논문 상세보기

대한소화기학회> Gut and Liver> Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study

KCI등재

Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study

Gwang Ha Kim , Hang Lak Lee , Moon Kyung Joo , Hong Jun Park , Sung Woo Jung , Ok-jae Lee , Hyungkil Kim , Hoon Jai Chun , Soo Teik Lee , Ji Won Kim , Han Ho Jeon , Il-kwun Chung , Hyun-soo Kim , Dong Ho Lee , Kyoung-oh Kim , Yun Jeong Lim , Seun-ja Park , Soo-jeong Cho , Byung-wook Kim , Kwang Hyun Ko , Seong Woo Jeon , Jae Gyu Kim , In-kyung Sung , Tae Nyeun Kim , Jae Kyu Sung , Jong-jae Park
  • : 대한소화기학회
  • : Gut and Liver 15권6호
  • : 연속간행물
  • : 2021년 11월
  • : 841-850(10pages)
Gut and Liver

DOI


목차

INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
CONFLICTS OF INTEREST
AUTHOR CONTRIBUTIONS
ORCID
REFERENCES

키워드 보기


초록 보기

Background/Aims: The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of Mucosta (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis.
Methods: This double-blind, active control, noninferiority, multicenter, phase 3 clinical trial randomly assigned 475 patients with endoscopically proven erosive gastritis to two groups: AD-203 twice daily or Mucosta thrice daily for 2 weeks. The intention-to-treat (ITT) analysis included 454 patients (AD-203, n=229; Mucosta, n=225), and the per-protocol (PP) analysis included 439 patients (AD-203, n=224; Mucosta, n=215). The posttreatment assessments included the primary (erosion improvement rate) and secondary endpoints (erosion and edema cure rates; improvement rates of redness, hemorrhage, and gastrointestinal symptoms). Drug-related adverse events were evaluated.
Results: According to the ITT analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta-treated patients were 39.7% and 43.8%, respectively. According to the PP analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta-treated patients were 39.3% and 43.7%, respectively. The one-sided 97.5% lower limit for the improvement rate difference between the study groups was -4.01% (95% confidence interval [CI], -13.09% to 5.06%) in the ITT analysis and -4.44% (95% CI, -13.65% to 4.78%) in the PP analysis. The groups did not significantly differ in the secondary endpoints in either analysis. Twenty-four AD-203-treated and 20 Mucosta-treated patients reported adverse events but no serious adverse drug reactions; both groups presented similar adverse event rates.
Conclusions: The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (Mucosta) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis. (Gut Liver 2021;15:841-850)

UCI(KEPA)

I410-ECN-0102-2022-500-000859979

간행물정보

  • : 의약학분야  > 내과학
  • : KCI등재
  • :
  • : 격월
  • : 1976-2283
  • : 2005-1212
  • : 학술지
  • : 연속간행물
  • : 2007-2022
  • : 1486


저작권 안내

한국학술정보㈜의 모든 학술 자료는 각 학회 및 기관과 저작권 계약을 통해 제공하고 있습니다.

이에 본 자료를 상업적 이용, 무단 배포 등 불법적으로 이용할 시에는 저작권법 및 관계법령에 따른 책임을 질 수 있습니다.

16권4호(2022년 07월) 수록논문
최근 권호 논문
| | | |

KCI등재

1Role of Tegoprazan in Helicobacter pylori Eradication Therapy

저자 : Jin Lee

발행기관 : 대한소화기학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 493-494 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

2Is the Risk for Venous Thromboembolism in East Asian Patients with Inflammatory Bowel Disease Comparable to That in Western Patients?

저자 : Sung Wook Hwang

발행기관 : 대한소화기학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 495-496 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

3Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions

저자 : Jung Il Lee

발행기관 : 대한소화기학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 497-498 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

4Revolution of Novel Direct Peroral Cholangioscopy: Another Step Beyond Limitations

저자 : Tanyaporn Chantarojanasiri

발행기관 : 대한소화기학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 499-500 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

5Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease

저자 : Eun Ae Kang , Jae Hee Cheon

발행기관 : 대한소화기학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 501-502 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

6Management of Helicobacter pylori Infection: A Comparison between Korea and the United States

저자 : Sung Eun Kim , Joo Ha Hwang

발행기관 : 대한소화기학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 503-514 (12 pages)

다운로드

(기관인증 필요)

초록보기

Helicobacter pylori has been well known to cause gastritis, peptic ulcers, mucosa-associated lymphoid tissue, and gastric cancer. The importance of H. pylori eradication has been emphasized; however, the management of H. pylori infection is difficult in clinical practice. In both Eastern and Western countries, there has been a constant interest in confirming individuals who should be tested and treated for H. pylori infection and developing methods to diagnose H. pylori infection. Many studies have been implemented to successfully eradicate H. pylori, and various combinations of eradication regimens for H. pylori infection have been suggested worldwide. Based on the findings of previous studies, a few countries have published their own guidelines that are appropriate for their country; however, these country-specific guidelines may differ depending on the circumstances in each country. Evidence-based guidelines and clinical practice updates for the treatment of H. pylori infection have been published in Korea and the United States in 2021. This review will summarize the similarities and differences in the management of H. pylori infection in Korea and the United States, focusing on indications, diagnosis, and treatments based on recent guidelines and recommendations in both countries. (Gut Liver 2022;16:503-514)

KCI등재

7Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

저자 : Jia-feng Wu

발행기관 : 대한소화기학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 515-524 (10 pages)

다운로드

(기관인증 필요)

초록보기

During the past decade, we have entered an era of biologics for the treatment of Crohn's disease and ulcerative colitis. The therapeutic goal of inflammatory bowel disease (IBD) management has evolved from symptom control and clinical remission to mucosal healing or even deep remission. Histological remission for ulcerative colitis and transmural healing of Crohn's disease are potential future goals. With the adoption of the treat-to-target concept, and given the need for tight control of IBD activity, therapeutic drug monitoring (TDM) is an important element of precision medicine. TDM involves the measurement of serum biologics and anti-drug antibodies levels, to confirm whether the right drug with the right dosage was prescribed to reach the right serum levels. TDM may help clinicians adjust biologics based on objective biomarkers instead of using empirical dosage escalation or making symptom-based therapeutic adjustments. Wellestablished reactive TDM algorithms have been proposed, and emerging evidence supports the clinical application of a proactive TDM strategy to enhance the duration of effective biologics and improve clinical outcomes. Recently, the proactive TDM strategy was shown to avoid the secondary loss of response to biologics, and improve long-term clinical outcomes in IBD patients. This review summarizes data from trials, and practice guidelines, on the clinical application of proactive and reactive TDM strategies for the daily care of biologic-treated IBD patients. (Gut Liver 2022;16:515-524)

KCI등재

8Endoscopic Reintervention for Recurrence of Malignant Biliary Obstruction: Developing the Best Strategy

저자 : Mamoru Takenaka , Masatoshi Kudo

발행기관 : 대한소화기학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 525-534 (10 pages)

다운로드

(기관인증 필요)

초록보기

Drainage therapy for malignant biliary obstruction (MBO) includes trans-papillary endoscopic retrograde biliary drainage (ERBD), percutaneous transhepatic biliary drainage (PTBD), and transgastrointestinal endoscopic ultrasound-guided biliary drainage (EUS-BD). With the development of chemotherapy, many MBO cases end up needing endoscopic reintervention (E-RI) for recurrent biliary obstruction. To achieve a successful E-RI, it is necessary to understand the various findings regarding E-RI in MBO cases reported to date. Therefore, in this review, we focus on E-RI for ERBD of distal MBO, ERBD of hilar MBO, and EUS-BD. To plan an appropriate E-RI strategy for biliary stent occlusion for MBO, the following must be considered on a case-by-case basis: the urgency of the drainage, the cause of the occlusion, the original route of drainage (PTBD/ERBD/EUS-BD), the initial stent used (plastic stent or self-expandable metallic stent), and in the case of self-expandable metallic stents, the type used (fully covered or uncovered). Regardless of the original method of stent placement, if the inflammation caused by obstructive cholangitis is severe and/or the patient is in shock, PTBD should be considered as the first choice. Finally, it is important to keep in mind that in many cases, performing E-RI will be difficult. (Gut Liver 2022;16:525-534)

KCI등재

9Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial

저자 : Yoon Jin Choi , Yong Chan Lee , Jung Mogg Kim , Jin Il Kim , Jeong Seop Moon , Yun Jeong Lim , Gwang Ho Baik , Byoung Kwan Son , Hang Lak Lee , Kyoung Oh Kim , Nayoung Kim , Kwang Hyun Ko , Hye-kyung Jung

발행기관 : 대한소화기학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 535-546 (12 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.
Methods: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)- based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.
Results: In total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.
Conclusions: TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier NCT03317223). (Gut Liver 2022;16:535-546)

KCI등재

10Long-term Outcomes of Additional Endoscopic Treatments for Patients with Positive Lateral Margins after Endoscopic Submucosal Dissection for Early Gastric Cancer

저자 : Tae-se Kim , Byung-hoon Min , Yang Won Min , Hyuk Lee , Poong-lyul Rhee , Jae J. Kim , Jun Haeng Lee

발행기관 : 대한소화기학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 547-554 (8 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: It is uncertain whether additional endoscopic treatment may be chosen over surgery in patients with positive lateral margins (pLMs) as the only non-curative factor after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC). We aimed to compare the long-term outcomes of additional endoscopic treatments in such patients with those of surgery and elucidate the clinicopathological factors that could influence the treatment selection.
Methods: A total of 99 patients with 101 EGC lesions undergoing additional treatment after noncurative ESD with pLMs as the only non-curative factor were analyzed. Among them, 25 (27 lesions) underwent ESD, 29 (29 lesions) underwent argon plasma coagulation (APC), and 45 (45 lesions) underwent surgery. Clinicopathological characteristics and long-term outcomes were compared.
Results: Residual tumor was found in 73.6% of cases. The presence of multiple pLMs was associated with higher risk of residual tumor (p=0.046). During a median follow-up of 58.9 months, recurrent or residual lesions after additional ESD and APC were found in 4% (1/25) and 6.8% (2/29) of patients, respectively. However, all were completely cured with surgery or repeated ESD. There were no extragastric recurrences after additional endoscopic treatment. Lymph node metastasis was identified after additional surgery in one (2.2%) patient with an EGC showing histological heterogeneity.
Conclusions: Given the favorable long-term outcomes, additional ESD or APC may be an acceptable choice for patients with pLMs as the only non-curative factor after ESD for EGC. However, clincopathological characteristics such as multiple pLMs and histological heterogeneity should be considered in the treatment selection. (Gut Liver 2022;16:547-554)

12
권호별 보기
같은 권호 다른 논문
| | | | 다운로드

KCI등재

1Another Piece of Evidence for Early Administration of Biologics in Children with Crohn's Disease Who Start as an Inflammatory Phenotype

저자 : Hyuk Yoon

발행기관 : 대한소화기학회 간행물 : Gut and Liver 15권 6호 발행 연도 : 2021 페이지 : pp. 791-792 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

2Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis

저자 : Jaeyoung Chun

발행기관 : 대한소화기학회 간행물 : Gut and Liver 15권 6호 발행 연도 : 2021 페이지 : pp. 793-794 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

3The Future of Endoscopic Retrograde Cholangiopancreatography in Korea

저자 : Chang Min Cho

발행기관 : 대한소화기학회 간행물 : Gut and Liver 15권 6호 발행 연도 : 2021 페이지 : pp. 795-796 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

4What Is the Next in Developing Model to Predict Survival Outcomes of Resected Pancreatic Cancer?

저자 : Chang Moo Kang

발행기관 : 대한소화기학회 간행물 : Gut and Liver 15권 6호 발행 연도 : 2021 페이지 : pp. 797-798 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

5Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?

저자 : Soichiro Sue , Shin Maeda

발행기관 : 대한소화기학회 간행물 : Gut and Liver 15권 6호 발행 연도 : 2021 페이지 : pp. 799-810 (12 pages)

다운로드

(기관인증 필요)

초록보기

Vonoprazan (VPZ), a new potassium-competitive acid blocker, has been approved and used for Helicobacter pylori eradication in Japan. To date, many studies, as well as several systematic reviews and meta-analyses (MAs), have compared VPZ-based 7-day triple therapy with proton pump inhibitor (PPI)-based therapy. An MA of randomized controlled trials (RCTs) comparing first-line VPZ- with PPI-based triple therapy, the latter featuring amoxicillin (AMPC) and clarithromycin (CAM), found that approximately 30% of patients hosted CAM-resistant H. pylori; however, the reliability was poor because of high heterogeneity and a risk of selection bias. VPZ-based triple therapy is superior to PPI-based triple therapy for patients with CAM-resistant H. pylori, but not for those with CAM-susceptible H. pylori. An MA of non-RCTs found that second-line VPZ-based triple therapies were slightly (~2.6%) better than PPI-based triple therapies (with AMPC and metronidazole). However, the reliability of that MA was also low because of selection bias, confounding variables and a risk of publication bias; in addition, it is difficult to generalize the results because of a lack of data on antibiotic resistance. VPZ-based triple therapy (involving AMPC and sitafloxacin) was more effective than PPI-based triple therapy in a third-line setting, but a confirmatory RCT is needed. Non-RCT studies indicated that VPZ-based triple therapy involving CAM and metronidazole may be promising. Any further RCTs must explore the antibiotic-resistance status when evaluating the possible superiority of a potassium-competitive acid blocker. (Gut Liver 2021;15:799-810)

KCI등재

6Systematic Endoscopic Approach to Early Gastric Cancer in Clinical Practice

저자 : Gwang Ha Kim

발행기관 : 대한소화기학회 간행물 : Gut and Liver 15권 6호 발행 연도 : 2021 페이지 : pp. 811-817 (7 pages)

다운로드

(기관인증 필요)

초록보기

Early gastric cancers (EGCs) are defined as gastric cancers confined to the mucosa or submucosa, regardless of regional lymph node metastasis. The proportion of EGCs has been increasing due to the increase in screening endoscopy for gastric cancers; therefore, the paradigm shift from surgical resection to endoscopic resection as a treatment modality for selected EGCs is accelerating. For successful endoscopic resection of EGCs, it is important to detect EGCs at an early stage and to accurately predict the histological type, depth of invasion, and horizontal margins of the tumor. The diagnostic process of EGCs can be divided into three steps: presence diagnosis, qualitative diagnosis, and quantitative diagnosis. The presence diagnosis of EGCs is mainly based on two endoscopic findings: a well-demarcated lesion and irregularity in the color/surface pattern. Qualitative diagnosis refers to the prediction of histological type, which is mainly possible based on the macroscopic shape and color of the lesion. Quantitative diagnosis of EGCs consists of predicting the depth of invasion by detailed examination of the macroscopic morphology and determining horizontal margins using chromoendoscopy. Although advanced diagnostic modalities, such as endosonography or magnifying endoscopy, are helpful for the qualitative and quantitative diagnosis of EGCs, these modalities are not available in most hospitals. Therefore, it is still very important to evaluate EGCs systematically during conventional endoscopy for successful endoscopic treatment. (Gut Liver 2021;15:811-817)

KCI등재

7Risk Stratification of T1 Colorectal Cancer Metastasis to Lymph Nodes: Current Status and Perspective

저자 : Katsuro Ichimasa , Shin-ei Kudo , Hideyuki Miyachi , Yuta Kouyama , Masashi Misawa , Yuichi Mori

발행기관 : 대한소화기학회 간행물 : Gut and Liver 15권 6호 발행 연도 : 2021 페이지 : pp. 818-826 (9 pages)

다운로드

(기관인증 필요)

초록보기

With the widely spreading population-based screening programs for colorectal cancer and recent improvements in endoscopic diagnosis, the number of endoscopic resections in subjects with T1 colorectal cancer has been increasing. Some reports suggest that endoscopic resection prior to surgical resection of T1 colorectal cancer has no adverse effect on prognosis and contributes to this tendency. The decision on the need for surgical resection as an additional treatment after endoscopic resection of T1 colorectal cancer should be made according to the metastasis risk to lymph nodes based on histopathological findings. Because lymph node metastasis occurs in approximately 10% of patients with T1 colorectal cancer according to current international guidelines, the remaining 90% of patients may be at an increased risk of surgical resection and associated postoperative mortality, with no clinical benefit derived from unnecessary surgical resection. Although a more accurate prediction system for lymph node metastasis is needed to solve this problem, risk stratification for lymph node metastasis remains controversial. In this review, we focus on the current status of risk stratification of T1 colorectal cancer metastasis to lymph nodes and outline future perspectives. (Gut Liver 2021;15:818-826)

KCI등재

8Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels

저자 : Kanokwan Pinyopornpanish , Apinya Leerapun , Kanokporn Pinyopornpanish , Nipon Chattipakorn

발행기관 : 대한소화기학회 간행물 : Gut and Liver 15권 6호 발행 연도 : 2021 페이지 : pp. 827-840 (14 pages)

다운로드

(기관인증 필요)

초록보기

Nonalcoholic fatty liver disease (NAFLD) patients with diabetes constitute a subgroup of patients with a high rate of liver-related complications. Currently, there are no specific drug recommendations for these patients. Metformin, a conventional insulin sensitizer agent, has been widely prescribed in patients with diabetes. Metformin treatment has been shown to be effective at alleviating hepatic lipogenesis in animal models of NAFLD, with a variety of mechanisms being deemed responsible. To date, most studies have enrolled diabetic patients who are treated with metformin, with the drug being taken continuously throughout the study. Although evidence exists regarding the benefits of metformin for NAFLD in preclinical studies, reports on the efficacy of metformin in adult NAFLD patients have had some discrepancies regarding changes in liver biochemistry and hepatic fat content. Evidence has also suggested possible effects of metformin as regards the prevention of hepatocellular carcinoma tumorigenesis. This review was performed to comprehensively summarize the available in vitro, in vivo and clinical studies regarding the effects of metformin on liver steatosis for the treatment of adult NAFLD patients with diabetes. Consistent reports as well as controversial findings are included in this review, and the mechanistic insights are also provided. In addition, this review focuses on the efficacy of metformin as a monotherapy and as a combined therapy with other antidiabetic medications. (Gut Liver 2021;15:827-840)

KCI등재

9Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study

저자 : Gwang Ha Kim , Hang Lak Lee , Moon Kyung Joo , Hong Jun Park , Sung Woo Jung , Ok-jae Lee , Hyungkil Kim , Hoon Jai Chun , Soo Teik Lee , Ji Won Kim , Han Ho Jeon , Il-kwun Chung , Hyun-soo Kim , Dong H

발행기관 : 대한소화기학회 간행물 : Gut and Liver 15권 6호 발행 연도 : 2021 페이지 : pp. 841-850 (10 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of Mucosta (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis.
Methods: This double-blind, active control, noninferiority, multicenter, phase 3 clinical trial randomly assigned 475 patients with endoscopically proven erosive gastritis to two groups: AD-203 twice daily or Mucosta thrice daily for 2 weeks. The intention-to-treat (ITT) analysis included 454 patients (AD-203, n=229; Mucosta, n=225), and the per-protocol (PP) analysis included 439 patients (AD-203, n=224; Mucosta, n=215). The posttreatment assessments included the primary (erosion improvement rate) and secondary endpoints (erosion and edema cure rates; improvement rates of redness, hemorrhage, and gastrointestinal symptoms). Drug-related adverse events were evaluated.
Results: According to the ITT analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta-treated patients were 39.7% and 43.8%, respectively. According to the PP analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta-treated patients were 39.3% and 43.7%, respectively. The one-sided 97.5% lower limit for the improvement rate difference between the study groups was -4.01% (95% confidence interval [CI], -13.09% to 5.06%) in the ITT analysis and -4.44% (95% CI, -13.65% to 4.78%) in the PP analysis. The groups did not significantly differ in the secondary endpoints in either analysis. Twenty-four AD-203-treated and 20 Mucosta-treated patients reported adverse events but no serious adverse drug reactions; both groups presented similar adverse event rates.
Conclusions: The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (Mucosta) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis. (Gut Liver 2021;15:841-850)

KCI등재

10Risk Factors for Disease Behavior Evolution and Efficacy of Biologics in Reducing Progression in Pediatric Patients with Nonstricturing, Nonpenetrating Crohn's Disease at Diagnosis: A Single-Center Experience in Korea

저자 : Hyun Jin Kim , Seak Hee Oh , Sung Hee Lee , Yu-bin Kim , Dae Yeon Kim , Sang Hyoung Park , Byong Duk Ye , Suk-kyun Yang , Kyung Mo Kim

발행기관 : 대한소화기학회 간행물 : Gut and Liver 15권 6호 발행 연도 : 2021 페이지 : pp. 851-857 (7 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Recently, the treatment of Crohn's disease (CD) has changed to a treat-to-target strategy, in which disease progression is prevented with early intervention. We analyzed the long-term evolution of nonstricturing, nonpenetrating (B1) disease at diagnosis and factors related to disease evolution in pediatric CD.
Methods: We retrospectively analyzed 402 patients between 2000 and 2013 who were younger than 18 years and had B1 disease at CD diagnosis. The median follow-up was 6.1 years (range, 1 to 13 years). The cumulative probabilities of developing stricturing (B2) or penetrating (B3) disease and associations between risk factors and disease behavior evolution were evaluated.
Results: Among the 402 patients, 75 (18.7%) had B2 or B3 disease by the final follow-up. The cumulative probabilities of disease behavior evolution were 18.3%, 34.3%, and 50.9% at 5, 10, and 13 years, respectively. Patients whose disease progressed had an increased risk of intestinal resection (hazard ratio [HR], 3.61; 95% confidence interval [CI], 2.25 to 6.03; p<0.001). First-degree family history of inflammatory bowel disease (HR, 2.38; 95% CI, 1.07 to 5.28; p=0.032), isolated ileal involvement at diagnosis (HR, 7.55; 95% CI, 1.04 to 15.57; p=0.045), and positive anti-Saccharomyces cerevisiae antibody titers (HR, 2.10; 95% CI, 1.03 to 4.25; p=0.040) were associated with disease behavior evolution. Early treatment with biologics significantly reduced disease progression (HR, 0.46; 95% CI, 0.79 to 3.39; p=0.042).
Conclusions: This study suggests that early aggressive therapy should be considered in B1 behavior pediatric CD patients with risk factors of disease evolution to improve long-term outcomes. (Gut Liver 2021;15:851-857)

123
발행기관 최신논문
자료제공: 네이버학술정보
발행기관 최신논문
자료제공: 네이버학술정보

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기